Semaglutide
-
Semaglutide – a new drug from Novo Nordisk demonstrated significant reductions in blood sugar and weight in Diabetes
Feb 11, 2018The 40-week trial showed that people with type 2 diabetes treated with once-weekly semaglutide experienced statistically greater reductions in HbA1c and body weight compared to treatment with dulaglutide. Results from the SUSTAIN 7 trial, which investigated... -
Semaglutide demonstrated superior HbA1c reduction vs placebo as add-on to basal insulin alone
Sep 15, 2016News Hour: Semaglutide is a once-weekly investigational analogue of human glucagon-like peptide-1 (GLP-1) that stimulates insulin and suppresses glucagon secretion in a glucosedependent manner, while decreasing appetite and food intake. Novo Nordisk announced that semaglutide, an...
